Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06387498
Other study ID # 20-2286
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 28, 2020
Est. completion date December 30, 2027

Study information

Verified date May 2024
Source University of Colorado, Denver
Contact Leslie Appiah, MD
Phone 720-926-1970
Email LESLIE.APPIAH@CUANSCHUTZ.EDU
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The "Testicular Tissue Cryopreservation" study is open to a subset of patients facing disease or treatment regimens that could lead to infertility (gonadotoxic therapies). For some of these patients, experimental testicular tissue cryopreservation is the only fertility preservation option available. The overall objective of this study is to determine the feasibility and acceptability of testicular tissue cryopreservation in male patients of all ages who have a condition or will undergo a treatment that can cause infertility.


Description:

For male patients who currently have no options for fertility preservation, this research proposal will enable optimization of testicular tissue procurement and processing, cryopreservation, and diagnosis/elimination of malignant cell contamination to ensure safety for future fertility-restoring treatments. While results from animal models and human organ donor experiments support the efficacy of testicular tissue/cell cryopreservation for fertility preservation and subsequent restoration, rigorous safety and efficacy data in human patients who will undergo infertility-causing therapies is lacking. However, the patients being recruited for this study currently have no options for future therapies aimed at fertility preservation without the preservation of their testicular tissue/cells prior to treatment. Thus, the current study will provide a potential resource for future fertility restoration.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 30, 2027
Est. primary completion date December 30, 2027
Accepts healthy volunteers No
Gender Male
Age group N/A and older
Eligibility Inclusion Criteria: 1. Male at any age. 2. Scheduled to undergo surgery, chemotherapy, drug treatment and/or radiation for the treatment or prevention of a medical condition or malignancy with risk of causing permanent and complete loss of subsequent testicular function. Be in significant risk of infertility as defined by: - Cyclophosphamide equivalent dose (CED) =4 g/m2 - Total body irradiation (TBI) - Testicular radiation >2.5 Gy - Cisplatin 500 mg/m2 - Bone Marrow Transplant (BMT) 3. Or have a medical condition or malignancy that requires removal of all or part of one or both testicles. 4. Or have newly diagnosed or recurrent disease. Those who were not enrolled at the time of initial diagnosis (i.e., patients with recurrent disease) are eligible if they have not previously received therapy that is viewed as likely to result in complete and permanent loss of testicular function. 5. Have two testicles if undergoing elective removal of a testicle for fertility preservation only. Note: removal of both testicles will limit fertility preservation options. 6. Sign an approved informed consent and authorization permitting the release of personal health information. The patient and/or the patient's legally authorized guardian must acknowledge in writing that consent for specimen collection has been obtained, in accordance with institutional policies approved by the U.S. Department of Health and Human Services. 7. Consent for serum tests for infectious diseases [including Hepatitis B Surface Antigen, Hepatitis C Virus (HCV) Antibody, and Human Immunodeficiency Virus (HIV) antigen/antibody screen to be performed at the time of testicular tissue harvesting. 8. Undergo a full history and physical examination and obtain standard pre-operative clearance (based on the most recent American College of Cardiology/American Heart Association (ACC/AHA) Guideline for Perioperative Cardiovascular Evaluation for Noncardiac Surgery) as determined by their primary surgeon. Exclusion Criteria Patients will be ineligible for participation in this study if they are: 1. Diagnosed with psychological, psychiatric, or other conditions which prevent giving fully informed consent. 2. Diagnosed with an underlying medical condition that significantly increases their risk of complications from anesthesia and surgery.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Testicular tissue biopsy and cryopreservation
Surgical Procurement of Testicular Tissue: At early stages of technology development, simple orchiectomy (removal of one entire testicle) may give the best chance of preserving sufficient cells for effective therapy. However, incisional biopsy of up to 25% of tissue from one testis (wedge resection) will also be presented to the patient as an alternative option. The amount of testicular parenchyma removed will be at the discretion of the surgeon.

Locations

Country Name City State
United States University of Colorado Aurora Colorado

Sponsors (1)

Lead Sponsor Collaborator
University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility, as Assessed via the Percentage of Eligible Patients who do a Procedure Determine feasibility of testicular tissue cryopreservation (TTC) in male patients receiving gonadotoxic therapies who desire fertility preservation. Calculated by the percentage of eligible patients that elect to proceed with TTC. Up 3 months after prescribed gonadotoxic therapy
Primary Feasibility, as Assessed via Percentage of Patients who Attempted a Procedure who were able to Cryopreserve Determine feasibility of testicular tissue cryopreservation (TTC) in male patients receiving gonadotoxic therapies who desire fertility preservation. Calculated by the number of study participants whose tissue was successfully cryopreserved. Up to 48 hours after testicular tissue biopsy
Primary Safety, as Assessed via the Number of Participants with At Least One Pre-specified Adverse Event The investigators will determine the safety of testicular tissue cryopreservation (TTC) in male patients receiving gonadotoxic therapies who desire fertility preservation. The number of participants with at least one of the following adverse events: 1) Bleeding, 2) Post-op infection, or 3) Long-term pain. Every six months throughout the life of the study (up to 7 years)
Primary Safety, as Assessed via the Number of Participants with At Least One Pre-specified Adverse Event The investigators will determine the safety of testicular tissue cryopreservation (TTC) in male patients receiving gonadotoxic therapies who desire fertility preservation. The number of participants with bleeding. 24 hours of the procedure
Primary Safety, as Assessed via the Number of Participants with At Least One Pre-specified The investigators will determine the safety of testicular tissue cryopreservation (TTC) in male patients receiving gonadotoxic therapies who desire fertility preservation. The number of participants with post-op infection. within 72 hours of the procedure
Primary Safety, as Assessed via the Number of Participants with At Least One Pre-specified The investigators will determine the safety of testicular tissue cryopreservation (TTC) in male patients receiving gonadotoxic therapies who desire fertility preservation. The number of participants with long-term pain. Assessed at 6 months
Secondary Acceptability, as Assessed via Annual Survey Regret Score The Decision Regret Scale measures distress or remorse after a health care decision. Possible scores range from 0-100, with higher scores indicating high regret. Annually until the age of majority for the male participant
See also
  Status Clinical Trial Phase
Recruiting NCT04519593 - ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma N/A
Recruiting NCT05980091 - Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration. Phase 1
Recruiting NCT06043609 - Outcome Evaluation After Fertility Preservation
Not yet recruiting NCT05048771 - Fertility and Temporality in Pediatric Oncology
Completed NCT05368194 - Food Intake and Epigenetic Alteration in the Spermatozoa of Singletons and Twins N/A
Recruiting NCT05176535 - Determination of Vaginal Colonization and the Effect of an Oral Probiotic (PROSALVAG) N/A
Recruiting NCT06360471 - Fertility Preservation and Pregnancy and Offspring Health Outcomes in Female Cancer
Recruiting NCT05271981 - Fertility After Uterine Artery Embolization
Recruiting NCT05815719 - Continuous Double Ovarian Stimulation. Phase 4
Recruiting NCT06127875 - Effects of Trying to Conceive Using an Home- or Hospital-based Ovulation Monitoring on Stress
Recruiting NCT05658848 - Effect of Collaborative Infertility Counseling on Coping Strategies and Marital Satisfaction N/A
Not yet recruiting NCT05385848 - Autologous Platelet-rich Plasma (PRP) Infusion to Improve Outcomes in Women With Ovarian Insufficiency: a Pilot Study N/A
Completed NCT04396210 - Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic
Completed NCT05134090 - Percutaneous Laparoscopy for Ovarian Tissue Cryopreservation.
Completed NCT05905289 - Survival and Reproductive Outcomes of Malignant Ovarian Germ Cell Tumors
Recruiting NCT05316467 - Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma Phase 2/Phase 3
Completed NCT04600869 - Effects of Naturalistic Decision-Making Model-based Oncofertility Care Education N/A
Withdrawn NCT04683237 - Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia Phase 2/Phase 3
Not yet recruiting NCT06179420 - The Effectiveness of Advanced Decision Support Tool (OPT-IVF) for IVF Treatment
Recruiting NCT06163079 - Assisted Reproductive Techniques (ART) With Sperm Donation : an Inclusive Model of ART for All Women